Pulmonary arterial hypertension targeted for new treatment by University of ÎÛÎÛ²ÝÝ®ÊÓÆµ scientists
Scientists at the University of ÎÛÎÛ²ÝÝ®ÊÓÆµ, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).